Vertex Pharma: Driving Growth Through Suzetrigine And Next …

Aug 2, 2024 · Vertex Pharmaceuticals has consistently outperformed the S&P 500 and iShares Biotechnology ETF, reflecting its robust growth and market position.

CouponFollow Extension

$10
OFF

Vertex Pharmaceuticals' Next Big Chapter? Vertex Stock Surges On ...

3 weeks from now

2 days ago · Vertex Pharmaceuticals could soon capture $10 billion in sales of non-opioid painkillers, an analyst said Friday as Vertex stock jumped.

investors.com

FAQs about Vertex Pharma: Driving Growth Through Suzetrigine And Next … Coupon?

Why did Vertex Pharmaceuticals stock surge 8 % after suzetrigine approval?

Vertex Pharmaceuticals shares surged 8 % in post-market trading on January 30 after securing FDA approval for Journavx, also known as suzetrigine. The drug is the company’s first-in-class non-opioid painkiller for moderate-to-severe acute pain. ...

Will suzetrigine become vertex's lead revenue-driver at peak sales?

Overall, I believe that once it gains regulatory approvals worldwide, Suzetrigine has the potential to become Vertex's lead revenue-driver, at peak sales. Thus increasing Vertex's long-term growth outlook. Vertex Pharma Q2 Pipeline Highlights ...

Is vertex preparing for a Phase 3 clinical trial of suzetrigine?

On the other hand, the company is also pursuing the evaluation of Suzetrigine on chronic pain management. In this sense, Vertex announced, in its Q2 earnings presentation, it is on track for a Q3 start of the pivotal Phase 3 clinical trial associated with Suzetrigine in DPN patients (see image below). ...

Will vertex share suzetrigine results in lumbosacral radiculopathy in late 2024?

Additionally, Vertex remains on track to share results in late 2024 from its Phase 2 study of suzetrigine in painful lumbosacral radiculopathy (LSR). Vertex will host an investor event on Sunday, October 20, 2024, at 6:00 p.m. ET in Philadelphia to discuss suzetrigine and the Phase 3 clinical trial results in acute pain. ...

Is Vertex Pharmaceuticals outperforming other biotech companies in 2022?

Despite healthcare sector struggles, Vertex Pharmaceuticals has outperformed both its biotech peers and the broader market since 2022. The company dominates the cystic fibrosis market and is expanding beyond it, with several promising late-stage programs. ...

Is Vertex Pharmaceuticals a good stock to buy in 2025?

Vertex Pharmaceuticals continues to execute its commercialization of three new drugs, JOURNAVX, CASGEVY, and ALYFTREK. Two of which have been approved by the FDA since December. Vertex's valuation appears high due to recent expenses, but analysts expect substantial earnings growth in 2025 as acquisition and clinical expenses subside. ...